StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)

Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –

Zevra Therapeutics cash

Cash and short-term investments held at the end of each period.

Zevra Therapeutics's cash was $221.57M at Jun 30, 2026. For fiscal 2025 it was $191.01M, up 174.9% from the year before. Over ten years it grew 14.0% a year on average. The highest annual figure on record is $191.01M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$191.01M+174.9%
FY2024Dec 31, 2024$69.50M+2.7%
FY2023Dec 31, 2023$67.70M-17.8%
FY2022Dec 31, 2022$82.37M-26.7%
FY2021Dec 31, 2021$112.35M+2566.7%
FY2020Dec 31, 2020$4.21M+31.0%
FY2019Dec 31, 2019$3.22M-85.2%
FY2018Dec 31, 2018$21.67M-48.7%
FY2017Dec 31, 2017$42.23M-38.7%
FY2016Dec 31, 2016$68.87M+34.2%
FY2015Dec 31, 2015$51.32M+400.4%
FY2014Dec 31, 2014$10.26M+420.8%
FY2013Dec 31, 2013$1.97M-22.5%
FY2012Dec 31, 2012$2.54M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$221.57M+9.4%
Q1 FY2026Mar 31, 2026$200.62M+220.3%
Q4 FY2025Dec 31, 2025$191.01M+174.9%
Q3 FY2025Sep 30, 2025$199.51M+123.2%
Q2 FY2025Jun 30, 2025$202.61M+311.3%
Q1 FY2025Mar 31, 2025$62.63M+18.8%
Q4 FY2024Dec 31, 2024$69.50M+2.7%
Q3 FY2024Sep 30, 2024$89.38M+7.8%
Q2 FY2024Jun 30, 2024$49.26M-43.3%
Q1 FY2024Mar 31, 2024$52.72M-29.3%
Q4 FY2023Dec 31, 2023$67.70M-17.8%
Q3 FY2023Sep 30, 2023$82.94M+9.3%
Q2 FY2023Jun 30, 2023$86.89M+7.3%
Q1 FY2023Mar 31, 2023$74.58M-26.6%
Q4 FY2022Dec 31, 2022$82.37M-26.7%
Q3 FY2022Sep 30, 2022$75.89M-42.3%
Q2 FY2022Jun 30, 2022$80.98M-38.8%
Q1 FY2022Mar 31, 2022$101.58M+33.8%
Q4 FY2021Dec 31, 2021$112.35M+2566.7%
Q3 FY2021Sep 30, 2021$131.50M+2396.7%
Q2 FY2021Jun 30, 2021$132.30M+1977.2%
Q1 FY2021Mar 31, 2021$75.92M+3122.3%
Q4 FY2020Dec 31, 2020$4.21M+31.0%
Q3 FY2020Sep 30, 2020$5.27M-19.2%
Q2 FY2020Jun 30, 2020$6.37M-12.8%
Q1 FY2020Mar 31, 2020$2.36M-82.5%
Q4 FY2019Dec 31, 2019$3.22M-85.2%
Q3 FY2019Sep 30, 2019$6.52M-50.0%
Q2 FY2019Jun 30, 2019$7.31M-74.1%
Q1 FY2019Mar 31, 2019$13.44M-61.2%
Q4 FY2018Dec 31, 2018$21.67M-48.7%
Q3 FY2018Sep 30, 2018$13.03M-71.9%
Q2 FY2018Jun 30, 2018$28.20M-48.3%
Q1 FY2018Mar 31, 2018$34.62M-43.4%
Q4 FY2017Dec 31, 2017$42.23M-38.7%
Q3 FY2017Sep 30, 2017$46.34M-28.3%
Q2 FY2017Jun 30, 2017$54.59M–
Q1 FY2017Mar 31, 2017$61.12M–
Q4 FY2016Dec 31, 2016$68.87M–
Q3 FY2016Sep 30, 2016$64.63M–

More Zevra Therapeutics figures

See a number that looks wrong?